← Back to Clinical Trials
Recruiting NCT05553223

NCT05553223 Micro-doses of Physical Activity for COPD

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT05553223
Status Recruiting
Phase
Sponsor University of British Columbia
Condition Chronic Obstructive Pulmonary Disease
Study Type INTERVENTIONAL
Enrollment 20 participants
Start Date 2022-10-12
Primary Completion 2026-09-01

Eligibility & Interventions

Sex All sexes
Min Age N/A
Max Age N/A
Study Type INTERVENTIONAL
Interventions
Microdoses of activity

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.

This trial targets 20 participants in total. It began in 2022-10-12 with a primary completion date of 2026-09-01.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

Chronic obstructive pulmonary disease (COPD) is a disease of the lungs that makes it hard for people to breath. Those with COPD spend considerably more time sitting and lying and less time performing physical activity than healthy individuals. Those who are the most sedentary have a greater risk of heart and blood vessel disease, which may lead to an early death. This project will investigate the effect of sitting still for 3 hours on blood vessel health in individuals with COPD. It will also investigate whether breaking up the amount of time patients sit with regular short bouts of walking (5 minutes each hour) at a comfortable pace chosen by the patient can have a positive effect on maintaining the health of their blood vessels. It is hypothesized that blood vessel health will be worse after 3 hours of sitting compared to when the sitting is broken up by short bouts of walking.

Eligibility Criteria

Inclusion Criteria: Non-smoking (\>6 months) patients with stable moderate-to-severe COPD (post bronchodilator forced expired volume in 1 sec/forced vital capacity\<0.7 and \<lower limit of normal, 30%\<Forced Expired Volume in 1 sec\<80% predicted and exacerbation free for \>6 weeks) will be recruited for the study. Exclusion Criteria: 1. performing structured exercise training (or pulmonary rehabilitation) 2. have a history of deep vein thrombosis 3. are on anticoagulant medication 4. have advanced cardiac or cerebrovascular disease (i.e. heart failure, previous stroke or myocardial infarction) 5. have diabetes 6. have musculoskeletal contraindications that limit their ability to perform physical activity 7. vascular ultrasound measurements cannot be obtained.

Contact & Investigator

Central Contact

Neil Eves, PhD

✉ neil.eves@ubc.ca

📞 250-807-9676

Frequently Asked Questions

Who can join the NCT05553223 clinical trial?

This trial is open to participants of all sexes, studying Chronic Obstructive Pulmonary Disease. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT05553223 currently recruiting?

Yes, NCT05553223 is actively recruiting participants. Contact the research team at neil.eves@ubc.ca for enrollment information.

Where is the NCT05553223 trial being conducted?

This trial is being conducted at Kelowna, Canada.

Who is sponsoring the NCT05553223 clinical trial?

NCT05553223 is sponsored by University of British Columbia. The trial plans to enroll 20 participants.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology